Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMVR6OM)

Drug Name

Flotetuzumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute biphenotypic leukaemia	2B33.4	Phase 2	[1]
Acute myeloid leukaemia	2A60	Phase 2	[2]
Myelodysplastic syndrome	2A37	Phase 1	[3]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 3 receptor alpha (IL3RA)	TTENHJ0	IL3RA_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Interleukin 3 receptor alpha (IL3RA)	DTT	IL3RA	1.807	3.926	2.678	3.573

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Acute biphenotypic leukaemia

ICD Disease Classification

2B33.4

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin 3 receptor alpha (IL3RA)	DTT	IL3RA	8.71E-54	0.98	2.64

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03739606) Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)